Talk to the Institute
Published mark

Ultragenyx Pharmaceutical Inc.

NASDAQ: RARE. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:0d171594-5056-4796-a2e8-c666d6937243
SEC CIK
0001515673
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 20, 2026
Newest evidence
Mar 27, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Emil D. Kakkis, M.D., Ph.D.President and Chief Executive Officer
Chair
Daniel G. Welch
Independent
Not published6 directors published
Published claims
232 distinct sources
Evidence records
30 pinned
Source conflicts
0None open

Built from 2 distinct sources and 3 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

DIRECTOR APPOINTED

Amrit Ray seat on Ultragenyx Pharmaceutical Inc., effective 2022-01-01.

EffectiveEffective Jan 1, 2022E3

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Chief Technical Operations Officer and Gene Therapy and Executive Vice PresidentDennis HuangNot capturedunknownSource reportedE2
President and Chief Executive OfficerEmil D. Kakkis, M.D., Ph.D.Not capturedunknownSource reportedE2
Chief Medical Officer and Executive Vice PresidentEric Crombez, M.D.Not capturedunknownSource reportedE2
Chief Commercial Officer and Executive Vice PresidentErik HarrisNot capturedunknownSource reportedE2
Chief Financial Officer, Corporate Strategy and Executive Vice PresidentHoward HornNot capturedunknownSource reportedE2
Chief Quality Officer and Executive Vice President of Translational SciencesJohn R. Pinion IINot capturedunknownSource reportedE2
Chief Legal Officer & Corporate Affairs and Executive Vice PresidentKarah ParschauerNot capturedunknownSource reportedE2

Board of directors

Evidence

6 directors published. Independence determinations are not published for every director.

DirectorStatusSinceCommitteesClaim
Amrit RayIndependence not published2022None publishedSource reportedE3
Corsee D. SandersIndependence not published2021None publishedSource reportedE3
Deborah DunsireIndependence not published2017None publishedSource reportedE3
Matthew K. FustIndependence not published2014None publishedSource reportedE3
Michael NarachiIndependence not published2015None publishedSource reportedE3
Shehnaaz SulimanIndependence not published2019None publishedSource reportedE3
Amrit Ray, M.D.IndependentNot publishedNone publishedSource reportedE2
Corsee D. Sanders, Ph.D.IndependentNot publishedNone publishedSource reportedE2
Daniel G. WelchIndependentChairNot publishedNone publishedSource reportedE2
Deborah Dunsire, M.D.IndependentNot publishedNone publishedSource reportedE2
Emil D. Kakkis, M.D., Ph.D.Not independentNot publishedChief Executive Officer and DirectorSource reportedE2
Shehnaaz Suliman, M.D.IndependentNot publishedNone publishedSource reportedE2

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
Chief Executive Officer and DirectorNot publishedEmil D. Kakkis, M.D., Ph.D.Not described in the published record

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerEmil D. Kakkis, M.D., Ph.D., President and Chief Executive Officer
Source reportedE2
company:0d171594-5056-4796-a2e8-c666d6937243:leadership_role:18
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingRARE (NASDAQ)
Source reportedE1
company:0d171594-5056-4796-a2e8-c666d6937243:security_listing:24
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 20, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameUltragenyx Pharmaceutical Inc.
Source reportedE1
company:0d171594-5056-4796-a2e8-c666d6937243:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:0d171594-5056-4796-a2e8-c666d6937243:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
3 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 20, 2026. Cited by 4 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    SEC DEF 14A 0001308179-26-000174
    sec def 14a. Published Mar 27, 2026. Retrieved Sep 12, 2026. Cited by 13 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    DEF 14A lrare2026_def14a.htm
    sec proxy. Published Mar 27, 2026. Retrieved Sep 2, 2026. Cited by 6 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 20, 2026
  • Amrit Ray seat on Ultragenyx Pharmaceutical Inc., effective 2022-01-01.
  • Corsee D. Sanders seat on Ultragenyx Pharmaceutical Inc., effective 2021-01-01.
  • Shehnaaz Suliman seat on Ultragenyx Pharmaceutical Inc., effective 2019-01-01.
  • Deborah Dunsire seat on Ultragenyx Pharmaceutical Inc., effective 2017-01-01.
  • Michael Narachi seat on Ultragenyx Pharmaceutical Inc., effective 2015-01-01.
  • Matthew K. Fust seat on Ultragenyx Pharmaceutical Inc., effective 2014-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:0d171594-5056-4796-a2e8-c666d6937243, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/ultragenyx-pharmaceutical-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership7
  4. Board12
  5. Committees1
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps17
  16. Linked people18
  17. Subject and corrections6
  18. Evidence3
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:0d171594-5056-4796-a2e8-c666d6937243
  • Cite this recordUltragenyx Pharmaceutical Inc.
  • Copy canonical URLregistry.alpha.ac/companies/ultragenyx-pharmaceutical-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    Ultragenyx Pharmaceutical Inc.Company
  • Dennis HuangPerson
  • Emil D. Kakkis, M.D., Ph.D.Person
  • Eric Crombez, M.D.Person
  • Erik HarrisPerson
  • Howard HornPerson
  • John R. Pinion IIPerson
  • Karah ParschauerPerson
  • Amrit RayPerson
  • Corsee D. SandersPerson
  • Deborah DunsirePerson
  • Matthew K. FustPerson
  • Michael NarachiPerson
  • Shehnaaz SulimanPerson
  • Amrit Ray, M.D.Person
  • Corsee D. Sanders, Ph.D.Person
  • Daniel G. WelchPerson
  • Deborah Dunsire, M.D.Person
  • Shehnaaz Suliman, M.D.Person
  • Sections
    OverviewUltragenyx Pharmaceutical Inc.
  • MonitoringUltragenyx Pharmaceutical Inc.
  • LeadershipUltragenyx Pharmaceutical Inc.
  • BoardUltragenyx Pharmaceutical Inc.
  • CommitteesUltragenyx Pharmaceutical Inc.
  • Control and votingUltragenyx Pharmaceutical Inc.
  • Authority to actUltragenyx Pharmaceutical Inc.
  • FinancialsUltragenyx Pharmaceutical Inc.
  • GovernanceUltragenyx Pharmaceutical Inc.
  • RiskUltragenyx Pharmaceutical Inc.
  • AI oversightUltragenyx Pharmaceutical Inc.
  • LegalUltragenyx Pharmaceutical Inc.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.